B-4T2001 is under clinical development by Bio4t2 and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how B-4T2001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
B-4T2001 overview
B4T2-001 is under development for the treatment of metastatic solid tumors including gastric or gastroesophageal junction adenocarcinoma, pancreatic cancer, non-small cell lung cancer, breast cancer and colorectal cancer. The therapeutic candidate comprises T cells genetically modified to express chimeric antigen receptors (CAR) targeting tumor associated antigens. It is being developed based on PrismCore, an artificial intelligence (AI) platform. It is administered through parenteral route.
Bio4t2 overview
Bio4t2 is a preclinical biopharmaceutical company developing single-target and combo-therapeutic CAR-T therapies targeting solid tumors. Bio4t2 is headquartered in San Diego, California, the US.
For a complete picture of B-4T2001’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
